Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Expert Panel Calls for Measures to Promote Commercialization of Results of Basic Research in Field of Healthcare
October 23, 2013
- DPJ Nagatsuma Requests Summoning Novartis President and Former Employee for Unsworn Diet Testimony
October 22, 2013
- Avastin to Receive Additional Indication for Ovarian Cancer: PAFSC’s Second Committee on Drugs
October 22, 2013
- Vaccine Policy Committee Agrees on Draft of Basic Vaccination Plan
October 22, 2013
- 72 Face-to-Face Consultations Provided from July 2011 through September 2013: PMDA
October 21, 2013
- Ex-Health Minister Nagatsuma Eyes Unsworn Diet Testimony by Ex-Novartis Employee on Diovan Scandal
October 18, 2013
- CSIMC’s Bill Payer, Industry Reps at Odds over Objective of Premium; “Elimination of Drug Lag” vs. “New Drug Development”
October 18, 2013
- 1st Committee on Drugs to Discuss Approval for JT’s Hyperphosphatemia Treatment on October 28
October 18, 2013
- 60% of Products/Indications in 1st Round of Development Requests Approved as of June: MHLW
October 18, 2013
- CSIMC Pricing Subcommittee OKs Indicator to Gauge Reasonableness of Premium’s Perpetuation
October 17, 2013
- CSIMC to Study Introduction of Medical Fee for DPC Hospitals with High Generic Drug Use Rates in Fee-for-Service System
October 17, 2013
- PMDA to Kick Off Pilot Program for Electronic Filings of NDA Data in October
October 16, 2013
- Japan “Hopes to Find Common Ground” in Upcoming TPP Talks on Intellectual Properties: Minister Amari
October 16, 2013
- Generic-Name Prescribing Promoted Use of Generic Drugs in FY2012: CSIMC Committee
October 11, 2013
- CSIMC Pricing Subcommittee to Explore “Responses” to Diovan Uproar
October 10, 2013
- Expert Group Calls for Handling of Switch OTC Drugs as Careful as Ethical Drugs in Early Stage after Switching
October 10, 2013
- Working Group Finalizes Recommendation on Rules for Online Sales of OTC Drugs
October 10, 2013
- MHLW Formally Compiles Interim Report of Expert Panel on Diovan Scandal
October 10, 2013
- Applications Based on Information in Public Domain Appropriate for 4 Drugs Including Vancomycin: Council on Unapproved Drugs
October 9, 2013
- Nonpartisan Lawmaker Group to Hold Study Session on Diovan Scandal
October 8, 2013
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…